Avelumab Alone or in Combination with Chemotherapy Versus Chemotherapy Alone in Platinum-Resistant or Platinum-Refractory Ovarian Cancer (JAVELIN Ovarian 200): An Open-Label, Three-Arm, Randomised, Phase 3 Study

Eric Pujade-Lauraine; Keiichi Fujiwara; Jonathan A. Ledermann; Amit M. Oza; Rebecca Kristeleit; Isabelle Laure Ray-Coquard; Gary E. Richardson; Cristiana Sessa; Kan Yonemori; Susana Banerjee; Alexandra Leary; Anna V. Tinker; Kyung Hae Jung; Radoslaw Madry; Sang Yoon Park; Charles K. Anderson; Fabian Zohren; Ross A. Stewart; Caimiao Wei; Samuel S. Dychter; Bradley J. Monk

doi:10.1097/OGX.0000000000000980

Avelumab Alone or in Combination with Chemotherapy Versus Chemotherapy Alone in Platinum-Resistant or Platinum-Refractory Ovarian Cancer (JAVELIN Ovarian 200): An Open-Label, Three-Arm, Randomised, Phase 3 Study

Eric Pujade-Lauraine, Keiichi Fujiwara, Jonathan A. Ledermann, Amit M. Oza, Rebecca Kristeleit, Isabelle Laure Ray-Coquard, Gary E. Richardson, Cristiana Sessa, Kan Yonemori, Susana Banerjee, Alexandra Leary, Anna V. Tinker, Kyung Hae Jung, Radoslaw Madry, Sang Yoon Park, Charles K. Anderson, Fabian Zohren, Ross A. Stewart, Caimiao Wei, Samuel S. DychterBradley J. Monk

Résultats de recherche: Contribution à un journal › !!Comment/debate

2 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	673-675
Nombre de pages	3
journal	Obstetrical and Gynecological Survey
Volume	76
Numéro de publication	11
Les DOIs	https://doi.org/10.1097/OGX.0000000000000980
état	Publié - 1 nov. 2021

Accès au document

10.1097/OGX.0000000000000980

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Pujade-Lauraine, E., Fujiwara, K., Ledermann, J. A., Oza, A. M., Kristeleit, R., Ray-Coquard, I. L., Richardson, G. E., Sessa, C., Yonemori, K., Banerjee, S., Leary, A., Tinker, A. V., Jung, K. H., Madry, R., Park, S. Y., Anderson, C. K., Zohren, F., Stewart, R. A., Wei, C., ... Monk, B. J. (2021). Avelumab Alone or in Combination with Chemotherapy Versus Chemotherapy Alone in Platinum-Resistant or Platinum-Refractory Ovarian Cancer (JAVELIN Ovarian 200): An Open-Label, Three-Arm, Randomised, Phase 3 Study. Obstetrical and Gynecological Survey, 76(11), 673-675. https://doi.org/10.1097/OGX.0000000000000980

Pujade-Lauraine, Eric ; Fujiwara, Keiichi ; Ledermann, Jonathan A. et al. / Avelumab Alone or in Combination with Chemotherapy Versus Chemotherapy Alone in Platinum-Resistant or Platinum-Refractory Ovarian Cancer (JAVELIN Ovarian 200) : An Open-Label, Three-Arm, Randomised, Phase 3 Study. Dans: Obstetrical and Gynecological Survey. 2021 ; Vol 76, Numéro 11. p. 673-675.

@article{b3deb976c11641ba92e310f3e08ff432,

title = "Avelumab Alone or in Combination with Chemotherapy Versus Chemotherapy Alone in Platinum-Resistant or Platinum-Refractory Ovarian Cancer (JAVELIN Ovarian 200): An Open-Label, Three-Arm, Randomised, Phase 3 Study",

author = "Eric Pujade-Lauraine and Keiichi Fujiwara and Ledermann, {Jonathan A.} and Oza, {Amit M.} and Rebecca Kristeleit and Ray-Coquard, {Isabelle Laure} and Richardson, {Gary E.} and Cristiana Sessa and Kan Yonemori and Susana Banerjee and Alexandra Leary and Tinker, {Anna V.} and Jung, {Kyung Hae} and Radoslaw Madry and Park, {Sang Yoon} and Anderson, {Charles K.} and Fabian Zohren and Stewart, {Ross A.} and Caimiao Wei and Dychter, {Samuel S.} and Monk, {Bradley J.}",

year = "2021",

month = nov,

day = "1",

doi = "10.1097/OGX.0000000000000980",

language = "English",

volume = "76",

pages = "673--675",

journal = "Obstetrical and Gynecological Survey",

issn = "0029-7828",

number = "11",

}

Pujade-Lauraine, E, Fujiwara, K, Ledermann, JA, Oza, AM, Kristeleit, R, Ray-Coquard, IL, Richardson, GE, Sessa, C, Yonemori, K, Banerjee, S, Leary, A, Tinker, AV, Jung, KH, Madry, R, Park, SY, Anderson, CK, Zohren, F, Stewart, RA, Wei, C, Dychter, SS & Monk, BJ 2021, 'Avelumab Alone or in Combination with Chemotherapy Versus Chemotherapy Alone in Platinum-Resistant or Platinum-Refractory Ovarian Cancer (JAVELIN Ovarian 200): An Open-Label, Three-Arm, Randomised, Phase 3 Study', Obstetrical and Gynecological Survey, VOL. 76, Numéro 11, p. 673-675. https://doi.org/10.1097/OGX.0000000000000980

Avelumab Alone or in Combination with Chemotherapy Versus Chemotherapy Alone in Platinum-Resistant or Platinum-Refractory Ovarian Cancer (JAVELIN Ovarian 200): An Open-Label, Three-Arm, Randomised, Phase 3 Study. / Pujade-Lauraine, Eric; Fujiwara, Keiichi; Ledermann, Jonathan A. et al.
Dans: Obstetrical and Gynecological Survey, Vol 76, Numéro 11, 01.11.2021, p. 673-675.

Résultats de recherche: Contribution à un journal › !!Comment/debate

TY - JOUR

T1 - Avelumab Alone or in Combination with Chemotherapy Versus Chemotherapy Alone in Platinum-Resistant or Platinum-Refractory Ovarian Cancer (JAVELIN Ovarian 200)

T2 - An Open-Label, Three-Arm, Randomised, Phase 3 Study

AU - Pujade-Lauraine, Eric

AU - Fujiwara, Keiichi

AU - Ledermann, Jonathan A.

AU - Oza, Amit M.

AU - Kristeleit, Rebecca

AU - Ray-Coquard, Isabelle Laure

AU - Richardson, Gary E.

AU - Sessa, Cristiana

AU - Yonemori, Kan

AU - Banerjee, Susana

AU - Leary, Alexandra

AU - Tinker, Anna V.

AU - Jung, Kyung Hae

AU - Madry, Radoslaw

AU - Park, Sang Yoon

AU - Anderson, Charles K.

AU - Zohren, Fabian

AU - Stewart, Ross A.

AU - Wei, Caimiao

AU - Dychter, Samuel S.

AU - Monk, Bradley J.

PY - 2021/11/1

Y1 - 2021/11/1

UR - http://www.scopus.com/inward/record.url?scp=85122616881&partnerID=8YFLogxK

U2 - 10.1097/OGX.0000000000000980

DO - 10.1097/OGX.0000000000000980

M3 - Comment/debate

AN - SCOPUS:85122616881

SN - 0029-7828

VL - 76

SP - 673

EP - 675

JO - Obstetrical and Gynecological Survey

JF - Obstetrical and Gynecological Survey

IS - 11

ER -

Pujade-Lauraine E, Fujiwara K, Ledermann JA, Oza AM, Kristeleit R, Ray-Coquard IL et al. Avelumab Alone or in Combination with Chemotherapy Versus Chemotherapy Alone in Platinum-Resistant or Platinum-Refractory Ovarian Cancer (JAVELIN Ovarian 200): An Open-Label, Three-Arm, Randomised, Phase 3 Study. Obstetrical and Gynecological Survey. 2021 nov. 1;76(11):673-675. doi: 10.1097/OGX.0000000000000980